Publications by authors named "Jacques J Col"

Claim this Profile
T
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Kenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, Robert M Califf, Elliott M Antman, Jacques J Col

Circ Cardiovasc Qual Outcomes· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
Sarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, Glenn N Levine, James J Ferguson, Jacques J Col

Int J Cardiol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Kenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, Glenn N Levine, Richard Gallo, Jacques J Col

Int J Cardiol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
C Michael Gibson, Yuri B Pride, Philip E Aylward, Jacques J Col, Shaun G Goodman

J Thromb Thrombolysis· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Kenneth W Mahaffey, Qinghong Yang, Karen S Pieper, Elliott M Antman, Harvey D White, Jacques J Col

J Gen Intern Med· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Marc Cohen, Kenneth W Mahaffey, Karen Pieper, Charles V Pollack, Elliott M Antman, Jacques J Col

J Am Coll Cardiol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Kenneth W Mahaffey, Marc Cohen, Jyotsna Garg, Elliott Antman, Neal S Kleiman, Jacques J Col

JAMA· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
Kamal A Al-Shwafi, Antoine de Meester, Bruno Pirenne, Jacques J Col

Am Heart J· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis